Timo Vesikari

Norovirus Vaccines in Pipeline Development

Timo Vesikari, 2021, Pediatric Vaccines and Vaccinations.

Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents

Robert E. O'Neill, Kathrin U. Jansen, Jacek Wysocki, 2015, Journal of the Pediatric Infectious Diseases Society.

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

Ivan S F Chan, Timo Vesikari, K. Schmader, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Lidia Oostvogels, Jan Smetana, Daisuke Watanabe, 2016, The New England journal of medicine.

Burden of Rotavirus Disease in European Union Countries

Timo Vesikari, J. Mrukowicz, T. Vesikari, 2006, The Pediatric infectious disease journal.

Hospital bed occupancy for rotavirus and all cause acute gastroenteritis in two Finnish hospitals before and after the implementation of the national rotavirus vaccination program with RotaTeq®

Matti Uhari, Marjo Renko, Timo Vesikari, 2014, BMC Health Services Research.

Norovirus GII-4 causes a more severe gastroenteritis than other noroviruses in young children.

Heini Huhtala, Timo Vesikari, H. Huhtala, 2011, The Journal of infectious diseases.